Oncolytics Biotech Set for Breakout on Promising Trial Data
AI Prediction of Oncolytics Biotech Inc. (ONCY)
Oncolytics Biotech is poised for potential growth due to its lead candidate, Pelareorep, targeting gastrointestinal cancers with upcoming significant catalysts including interim data from clinical trials.
Oncolytics Biotech focuses on developing Pelareorep, an immunotherapeutic agent targeting various cancers, with an emphasis on gastrointestinal cancers. The company is currently engaged in multiple Phase 2 clinical trials, particularly for colorectal and pancreatic cancers. Pelareorep has shown promising results in earlier trials, and interim data expected by the end of 2026 could be a significant catalyst. The company's strategic shift to the U.S. and its focus on securing additional financing through strategic partnerships augment its potential for operational success and growth. The upcoming clinical data, if positive, could substantially impact the company's valuation and stock price.
ONCY Report Information
Prediction Date2026-04-02
Close @ Prediction$0.93
Mkt Cap111m
IPO DateN/a
AI-derived Information
Recent News for ONCY
- Jul 13, 10:13 am — Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY) (InvestorsHub)
- Jul 13, 9:00 am — Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial (GlobeNewswire RSS)
- Jun 16, 12:42 pm — ONCY Stock Surged Today Heres What Securing A Key Immunotherapy Patent Means For Oncolytics (Stocktwits)
- Jun 16, 9:05 am — ONCY files 8-K with clinical-trial language (ScanScor Filing Bot)
- Jun 16, 9:00 am — Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 (GlobeNewswire RSS)
- Jun 2, 9:00 am — Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer (GlobeNewswire RSS)
- Jun 1, 11:26 am — ONCY Stock Heads For Sixth Straight Session Of Gains Lead Therapy Shines in Early Combination Treatment Study (Stocktwits)
- Jun 1, 9:00 am — Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches (GlobeNewswire RSS)
- May 26, 9:00 am — From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story (ACCESSWIRE)
- May 22, 9:00 am — Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors (GlobeNewswire RSS)
- May 6, 6:48 pm — Oncolytics Biotech Reports Data in Colorectal Cancer Study (IPO-Edge.com)
- May 4, 9:00 am — Oncolytics Biotech Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer (GlobeNewswire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest